Premium
Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programme
Author(s) -
Danese Silvio,
Subramaniam Kavitha,
Van Zyl Jan,
Adsul Shashi,
Lindner Dirk,
Roth Jeannine,
Vermeire Séverine
Publication year - 2021
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.16160
Subject(s) - vedolizumab , medicine , persistence (discontinuity) , disease , engineering , inflammatory bowel disease , geotechnical engineering
Summary Background Vedolizumab was shown to be effective and safe for patients with ulcerative colitis (UC) or Crohn's disease (CD) in the GEMINI phase 3 and long‐term safety (LTS) studies. Aim To report treatment persistence and safety results up to 2 years after enrolment in the vedolizumab extended access programme (XAP) Methods Vedolizumab XAP is a phase 3b/4, prospective, open‐label, multinational, interventional study. At rollover from GEMINI LTS, patients who were experiencing continued clinical benefit with vedolizumab received reduced dosing frequency from every 4 weeks (Q4W) to every 8 weeks (Q8W). Patient persistence on Q8W dosing, incidence of relapse, and safety 2 years after enrolment were investigated. Results We enrolled 311 patients (142 UC and 169 CD). At baseline, 93.7% (UC) and 89.3% (CD) of patients were in clinical remission; 93.0% (UC) and 84.6% (CD) reduced dosing frequency to Q8W at enrolment. Of those who reduced dosing frequency to Q8W at enrolment, 93.9% (UC) and 91.6% (CD) remained on Q8W dosing; 6.1% (UC) and 8.4% (CD) re‐escalated to Q4W dosing. Relapse was reported in 9.1% (UC) and 14.0% (CD) of patients who reduced dosing to Q8W. Adverse events related to vedolizumab were infrequent; no new events were reported. Conclusion We observed high patient persistence on vedolizumab Q8W in the first 2 years after the reduction of dosing frequency in the XAP along with low rates of Q4W dose re‐escalation and relapse. The safety profile was consistent with previous reports. ClinicalTrials.gov: NCT02743806.